Onxeo announces acquisition of DNA Therapeutics and provides update on Validive® development plan // DANISH TRANSLATION: Onxeo offentliggør opkøb af DNA Therapeutics og giver en opdatering om udviklingsplanen for Validive®

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment  Acquisition expands Company’s R&D pipeline and opens new opportunities in orphan oncology indications Further development of Validive® to be conducted in partnership Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company…read more →